인간 인슐린 시장 규모, 점유율, 성장 분석 : 제품별, 유형별, 브랜드별, 전달 디바이스별, 당뇨병별, 지역별 - 산업 예측(2025-2032년)
Human Insulin Market Size, Share, and Growth Analysis, By Product (HI Drugs, HI Delivery Devices), By Type (Insulin Analogs and Biosimilars, HI Biologics), By Brand, By Delivery Devices, By Diabetes, By Region - Industry Forecast 2025-2032
상품코드:1670220
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 02월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
인간 인슐린 시장 규모는 2023년 193억 7,000만 달러로 평가되며, 2024년 202억 8,000만 달러에서 2032년 292억 9,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 4.7%의 CAGR로 성장할 것으로 예상됩니다.
인간 인슐린 시장은 당뇨병 관리에 매우 중요하며, 제1형 및 제2형 당뇨병 환자 수백만 명에게 필수적인 치료제를 제공하고 있습니다. 국제당뇨병연맹은 2019년 4억 6,300만 명의 성인 당뇨병 환자가 2045년 7억 명으로 증가할 것으로 예상하고 있으며, 인슐린에 대한 수요가 크게 증가하여 시장 성장을 견인할 것으로 예상됩니다. 제조 기술, 특히 재조합 DNA 기술의 발달로 보다 안전하고 효과적인 인슐린이 개발되어 환자들의 수용성이 높아지고 있습니다. 의료 기관, 정부, NGO 간의 협력은 특히 저소득층 지역에서 인슐린에 대한 인식을 높이고 접근성을 개선하는 것을 목표로 하고 있습니다. 그러나 높은 제조 비용과 규제상의 문제로 인해 인슐린의 접근성을 높이는 데 어려움을 겪고 있습니다. 아날로그 인슐린으로의 전환, 펜이나 펌프와 같은 혁신적인 전달 장치의 인기 증가, AI의 통합을 통한 보완은 치료 순응도를 높이고 시장을 확대하는 데 있어 주목할 만한 추세입니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
인간 인슐린 시장 규모 : 제품별 & CAGR(2025-2032년)
시장 개요
HI 드러그
HI 딜리버리 디바이스
인간 인슐린 시장 규모 : 유형별 & CAGR(2025-2032년)
시장 개요
인슐린 아날로그와 바이오시밀러
즉효성
장시간 작용형
프리믹스
HI 바이오로직스
단시간 작용형
중간 작용형
프리믹스
인간 인슐린 시장 규모 : 브랜드별 & CAGR(2025-2032년)
시장 개요
HI 유사체 및 바이오시밀러
antus
NovoRapid/Novolog
Humalog
기타 브랜드
HI 바이오로직스
Actrapid, Insulatard, and Mixtard
Humulin
Insuman
인간 인슐린 시장 규모 : 전달 디바이스별 & CAGR(2025-2032년)
시장 개요
펜
재사용 가능
일회용
펜 바늘
표준
안전
주사기
인간 인슐린 시장 규모 : 당뇨병별 & CAGR(2025-2032년)
시장 개요
1형 당뇨병
2형 당뇨병
인간 인슐린 시장 규모 : 지역별 & CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
최근의 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년비 비교(2022-2024년)
주요 기업 개요
Novo Nordisk(Denmark)
Eli Lilly and Company(United States)
Sanofi(France)
Biocon Limited(India)
Pfizer Inc.(United States)
Merck & Co., Inc.(United States)
AstraZeneca(United Kingdom)
Boehringer Ingelheim(Germany)
Tonghua Dongbao Pharmaceutical Co., Ltd.(China)
Wockhardt(India)
Julphar(United Arab Emirates)
Oramed Pharmaceuticals Inc.(United States)
Adocia(France)
MannKind Corporation(United States)
Gan & Lee Pharmaceuticals(China)
Ypsomed(Switzerland)
Medtronic(Ireland)
Dexcom(United States)
Insulet Corporation(United States)
Senseonics Holdings, Inc.(United States)
결론과 제안
ksm
영문 목차
영문목차
Human Insulin Market size was valued at USD 19.37 billion in 2023 and is poised to grow from USD 20.28 billion in 2024 to USD 29.29 billion by 2032, growing at a CAGR of 4.7% during the forecast period (2025-2032).
The human insulin market is crucial for diabetes management, providing essential treatment to millions impacted by type 1 and type 2 diabetes. With the International Diabetes Federation projecting an increase from 463 million diabetic adults in 2019 to 700 million by 2045, the demand for insulin is expected to rise significantly, driving market growth. Advances in production techniques, particularly recombinant DNA technology, have led to the development of safer and more effective insulin, enhancing patient acceptance. Collaborations among healthcare organizations, governments, and NGOs aim to raise awareness and improve insulin accessibility, especially in low-income regions. However, high production costs and regulatory challenges hinder affordability. The shift towards analog insulins and the rising popularity of innovative delivery devices like pens and pumps, supplemented by AI integration, are notable trends in enhancing treatment adherence and market expansion.
Top-down and bottom-up approaches were used to estimate and validate the size of the Human Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Human Insulin Market Segments Analysis
Global Human Insulin Market is segmented by Product, Type, Brand, Delivery Devices, Diabetes and region. Based on Product, the market is segmented into HI Drugs and HI Delivery Devices. Based on Type, the market is segmented into Insulin Analogs and Biosimilars and HI Biologics. Based on Brand, the market is segmented into HI Analogs and Biosimilars and HI Biologics. Based on Delivery Devices, the market is segmented into Pens, Pen Needles and Syringes. Based on Diabetes, the market is segmented into Type I Diabetes and Type II Diabetes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Human Insulin Market
The expanding incidence of diabetes globally serves as a critical catalyst for the human insulin market. According to the International Diabetes Federation, approximately 463 million adults had diabetes in 2019, with predictions forecasting that this figure could soar to 700 million by 2045. This escalating diabetic population intensifies the need for insulin, thereby propelling market growth. Notably, nations such as China and India have experienced a notable rise in diabetes cases, attributed to shifts in lifestyle and dietary practices, which in turn has spurred an increased requirement for human insulin to manage these conditions effectively.
Restraints in the Human Insulin Market
The human insulin market faces several constraints primarily due to regulatory challenges and patent protections that limit competition and market entry. The process of acquiring regulatory approvals for new insulin products or biosimilars is demanding, necessitating thorough testing and adherence to strict guidelines, which can delay product availability. Furthermore, patent exclusivity on specific insulin formulations restricts the emergence of generic alternatives, thereby limiting choices for patients and hindering overall market expansion. For example, the exclusivity surrounding particular long-acting insulin analogs has effectively stifled the introduction of biosimilar options in the marketplace, exacerbating these constraints and impacting accessibility.
Market Trends of the Human Insulin Market
The Human Insulin market is currently experiencing a significant shift towards analog insulin formulations, driven by their superior benefits in diabetes management. Unlike traditional human insulin, which has limitations in terms of onset and duration, analog insulins provide rapid action and enhanced glycemic control, leading to improved patient outcomes. The rising adoption of long-acting analogs such as insulin glargine (Lantus) and insulin detemir (Levemir) has reshaped market dynamics, capturing substantial market share due to their favorable pharmacokinetic profiles. This trend underscores the growing preference among healthcare professionals and patients for precise insulin therapies, marking a transformative phase in diabetes treatment options.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Human Insulin Market Size by Product & CAGR (2025-2032)
Market Overview
HI Drugs
HI Delivery Devices
Global Human Insulin Market Size by Type & CAGR (2025-2032)
Market Overview
Insulin Analogs and Biosimilars
Rapid-acting
Long-acting
Premixed
HI Biologics
Short-acting
Intermediate-acting
Premixed
Global Human Insulin Market Size by Brand & CAGR (2025-2032)
Market Overview
HI Analogs and Biosimilars
Lantus
NovoRapid/Novolog
Humalog
Other Brands
HI Biologics
Actrapid, Insulatard, and Mixtard
Humulin
Insuman
Global Human Insulin Market Size by Delivery Devices & CAGR (2025-2032)
Market Overview
Pens
Reusable
Disposable
Pen Needles
Standard
Safety
Syringes
Global Human Insulin Market Size by Diabetes & CAGR (2025-2032)
Market Overview
Type I Diabetes
Type II Diabetes
Global Human Insulin Market Size & CAGR (2025-2032)
North America (Product, Type, Brand, Delivery Devices, Diabetes)
US
Canada
Europe (Product, Type, Brand, Delivery Devices, Diabetes)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Product, Type, Brand, Delivery Devices, Diabetes)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Product, Type, Brand, Delivery Devices, Diabetes)
Brazil
Rest of Latin America
Middle East & Africa (Product, Type, Brand, Delivery Devices, Diabetes)
